![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Maher, Toby M.; Brown, Kevin K.; Kreuter, Michael; Devaraj, Anand; Walsh, Simon L. F.; Lancaster, Lisa H.; Belloli, Elizabeth A.; Padilla, Maria; Behr, Jürgen; Goeldner, Rainer-Georg; Tetzlaff, Kay; Schlenker-Herceg, Rozsa und Flaherty, Kevin R.
(2022):
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
In: European Respiratory Journal, Bd. 59, Nr. 2, 2004587
2021
Deterding, Robin; Griese, Matthias; Deutsch, Gail; Warburton, David; DeBoer, Emily M.; Cunningham, Steven; Clement, Annick; Schwerk, Nicolaus; Flaherty, Kevin R.; Brown, Kevin K.; Voss, Florian; Schmid, Ulrike; Schlenker-Herceg, Rozsa; Verri, Daniela; Dumistracel, Mihaela; Schiwek, Marilisa; Stowasser, Susanne; Tetzlaff, Kay; Clerisme-Beaty, Emmanuelle und Young, Lisa R.
(2021):
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.
In: Erj Open Research, Bd. 7, Nr. 2, 00805-2020
2017
Koch, Andrea; Watz, Henrik; Maleki-Yazdi, M. Reza; Bothner, Ulrich; Tetzlaff, Kay; Voss, Florian und McGarvey, Lorcan
(2017):
Comprehensive assessment of the safety of olodaterol 5 mu g in the Respimat (R) device for maintenance treatment of COPD: comparison with the long-acting beta(2)-agonist formoterol.
In: Npj Primary Care Respiratory Medicine, Bd. 27, 60
[PDF, 591kB]